Acorda Therapeutics (ACORQ)
(Delayed Data from OTC)
$0.07 USD
-0.03 (-30.00%)
Updated Jul 26, 2024 03:29 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Acorda Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 118 | 119 | 129 | 153 | 192 |
Cost Of Goods | 15 | 30 | 41 | 34 | 35 |
Gross Profit | 102 | 88 | 88 | 119 | 158 |
Selling & Adminstrative & Depr. & Amort Expenses | 367 | 124 | 167 | 198 | 469 |
Income After Depreciation & Amortization | -265 | -35 | -79 | -78 | -312 |
Non-Operating Income | 0 | 30 | 0 | 1 | 59 |
Interest Expense | 32 | 30 | 30 | 31 | 22 |
Pretax Income | -296 | -35 | -109 | -108 | -274 |
Income Taxes | -43 | 31 | -5 | -8 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -253 | -66 | -104 | -100 | -273 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -253 | -66 | -104 | -100 | -273 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 37 | 14 | -29 | -16 | 15 |
Depreciation & Amortization (Cash Flow) | 302 | 50 | 50 | 62 | 326 |
Income After Depreciation & Amortization | -265 | -35 | -79 | -78 | -312 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.24 | 0.99 | 0.52 | 0.40 | 0.40 |
Diluted EPS Before Non-Recurring Items | -203.57 | -66.80 | -199.00 | -246.40 | -238.75 |
Diluted Net EPS (GAAP) | -203.57 | -66.80 | -195.80 | -246.40 | -689.86 |
Fiscal Year end for Acorda Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 20.29 | 37.99 | 27.72 | 29.68 |
Cost Of Goods | NA | 3.71 | 5.60 | 3.39 | 3.07 |
Gross Profit | NA | 16.58 | 32.39 | 24.33 | 26.61 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 36.20 | 279.71 | 26.85 | 30.24 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -19.62 | -247.32 | -2.52 | -3.63 |
Non-Operating Income | NA | 0.78 | -0.51 | 0.56 | 0.06 |
Interest Expense | NA | 8.44 | 8.21 | 7.98 | 7.77 |
Pretax Income | NA | -27.28 | -255.87 | -9.94 | -11.35 |
Income Taxes | NA | 0.11 | -38.11 | -1.06 | -1.97 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -27.40 | -217.76 | -8.89 | -9.38 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -27.40 | -217.76 | -8.89 | -9.38 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 1.24 | 1.24 | 1.24 | 1.24 |
Diluted EPS Before Non-Recurring Items | NA | -22.06 | -175.32 | -7.16 | -7.55 |
Diluted Net EPS (GAAP) | NA | -22.06 | -175.06 | -7.16 | -7.55 |